Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05829460CT.gov Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia | — | Withdrawn | — | — | — |
NCT05903131CT.gov Uterine Preservation Via Lifestyle Transformation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Levonorgestrel (this asset) | Washington University School of Medicine | P2 | CCC · 52 |
| Semaglutide | Washington University School of Medicine | P2 | CCC |
| Zanidatamab | UNICANCER | P2 | CCC |
| Irinotecan | Western Regional Medical Center | P1/2 | CCC |
| Capecitabine | Western Regional Medical Center | P1/2 | CCC |
| Pasifolate Exatecan | Elucida Oncology | P1/2 | CCC |
| Temsirolimus | Western Regional Medical Center | P1/2 | CCC |
| Nivolumab | Western Regional Medical Center | P1/2 | CCC |
| pf-08052666 | Seagen, a wholly owned subsidiary of Pfizer | P1 | CC |
+4 more in the Endometrial Disorder cohort
Other indications for Levonorgestrel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P4 | BB · 68 |
| Obesity Disorder | — | P4 | BB · 65 |
| Major Depressive Disorder | — | P4 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Levonorgestrel in Endometrial Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/levonorgestrel-endometrial-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →